IBA Health has had a mixed year. It has shown a profit this year and thought it had made a significant deal in the UK market for distributing its products. This has become un-stuck with the iSoft/Torex merger plan but IBA has solidified its position in Asia and in its home markets.
The company needs to rapidly attract the right partners globally and create a much stronger ecosystem. It claims to be more focused on the Asian markets but needs to be a player globally. The company also needs to continue its focus on earnings this year and continue with its acquisition program.
Our Vendor Analysis is our series of Profiles Reports on the Vendors. The Profiles include our Outlook, SWOT analysis and a detailed profile of the company.
